Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/Tacrolimus

Summary:

The induction of diabetes has been recognised as adverse effect of the immunsuppressive drug FK506/Tacrolimus. The aim of this study was to clarify whether insulinopenia or insulin resistance dominates and whether islet cell autoantibodies are present in patients treated by FK506. We investigated 58 patients 1-3 years after liver transplantation while under therapy with FK506 or CsA and prednisolone (0-7.5 mg) for basal blood glucose levels and islet-cell specific autoantibodies. A subgroup of 20 patients on FK506, 10 patients on cyclosporin and 15 healthy volunteers were metabolically tested by oGTT. Five patients had diabetes pre-transplantation. After transplantation, 9/28 FK506-treated patients developed newly diagnosed diabetes compared to 0/25 cyclosporin-treated patients (p < 0.01). Both patient groups showed significantly higher fasting blood glucose, insulin or C-peptide levels compared to controls. Through the oGTT, FK506-treated patients without diabetes, but not cyclosporin-treated patients, had higher C-peptide levels compared to controls (p < 0.05). Five/32 patients on FK506 compared to 0/26 patients on cyclosporin (p < 0.05) had islet cell specific autoantibodies, mainly ICA without GAD- or IA2-Ab, a feature described for latent autoimmune diabetes in adults. ICA positivity was correlated to the diabetes associated HLA haplotype DR4/DQ*0302 (p < 0.05). Although the interpretation of our metabolic data in patients with concomitant liver disease and prednisolone therapy has limitations, we suggest insulin resistance caused by treatment with FK506. However, manifestation of diabetes was associated with relative insulinopenia rather than insulin resistance in patients on FK506. Immunsuppressive therapy by FK506 was not able to suppress islet cell autoimmunity, and may even induce it in genetically predisposed patients.

Abbreviations: Ab antibodies; CsA Cyclosporine A; ICA islet cell antibodies; IGT impaired glucose tolerance; IRI immunreactive insulin; NGT normal glucose tolerance; oGTT oral glucose tolerance test; Tx transplantation

Tacrolismus/FK506 - diabetes mellitus - ICA

References

• 1 Chelmicka-Schorr E, Wiegmann K, Wollmann R, Arnason B GW, Kim D H. Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats.  J Autoimmun. 11 329-334 1998; 
• 2 Esmatjes E, Rodriguez-Villar C, Ricart M J, Casamitjana R S, Martorell J, Sabater L, Astudillo E, Fernandez-Cruz L. Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation.  Transplantation. 66 128-131 1998; 
• 3 European FK506 Multicentre Liver Study Group . Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection.  Lancet. 344 423-428 1994; 
• 4 Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects.  Endocr Rev. 19 477-490 1998; 
• 5 Gruessner R W. Tacrolimus in pancreas transplantation: a multicenter analysis.  Clin Transplant. 11 299-312 1997; 
• 6 Jaeger C, Brendel M D, Hering B J, Eckhard M, Bretzel R G. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts.  Diabetes. 46 1907-1910 1997; 
• 7 Jindal R M. Posttransplant diabetes mellitus - a review.  Transplantation. 58 1289-1298 1994; 
• 8 Kahn B B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance.  Cell. 92 593-599 1998; 
• 9 Krentz A J, Dousset B, Mayer D, McMaster P, Buckels J, Cramb R, Smith J M, Nattrass M. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients.  Diabetes. 42 1753-1759 1993; 
• 10 Lohmann T, Seissler J, Verlohren H J, Schröder S, Rötger J, Dähn K, Morgenthaler N, Scherbaum W A. Distinct genetic and immunological features in patients with insulin-dependent diabetes below and above age 40 at onset.  Diab Care. 20 524-529 1997; 
• 11 Pietropaolo M, Peakman M, Pietropaolo S L, Zanone M M, Foley T P, Becker D J, Trucco M. Combined analysis of GAD65 and ICA512 (IA-2) autoantibodies in organ and non-organ-specific autoimmune diseases confers high specifity for insulin-dependent diabetes mellitus.  J Autoimmun. 11 1-10 1998; 
• 12 Pirsch J D, Miller J, Deierhoi M H, Vincenti F, Filo R S. for the FK506 Kidney Transplant Study Group . A comparison of tacrolimus (FK506) and cyclosporine for immunosupression after cadaveric renal transplantation.  Transplantation. 64 977-983 1997; 
• 13 Redmon J B, Olson L K, Armstrong M B, Greene M J, Robertson P R. Effects of Tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells.  J Clin Invest. 98 2786-2793 1996; 
• 14 Seissler J, De Sonnaville J JJ, Morgenthaler N G, Steinbrenner H, Glawe D, Khoo-Morgenthaler U Y, Lan M S, Notkins A L, Heine R J, Scherbaum W A. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease.  Diabetol. 41 891-897 1998; 
• 15 Steinmüller T M, Gräf K-J, Schleicher J, Leder K, Bechstein W O, Mueller A R, Dette K, Schulz E, Neuhaus P. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial.  Transplantation. 58 669-674 1994; 
• 16 Thomson A W, Starzl T E. FK 506 and autoimmune disease: perspective and prospects.  Autoimmunity. 12 303-313 1992; 
• 17 Tyden G, Reinholt F P, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts.  N Engl J Med. 335 860-863 1996; 
• 18 Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited.  J Clin Invest. 101 86-96 1998; 
• 19 WHO/ADA . Report of the Expert Commitee on the diagnosis and classification of diabetes mellitus.  Diab Care. 20 1183-1197 1997; 
• 20 Wijnen R M, Ericzon B G. Update of tacrolimus in pancreas transplantation.  Diabet Med. 14 911-918 1997; 
• 21 Yoshioka K, Sato T, Okada N, Ishii T, Imanishi M, Tanaka S, Kim T, Sugimoto T, Fuji S. Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy.  Diab Res Clin Pract. 42 85-89 1998;